Viral and cellular requirements for entry of herpes simplex virus type 1 into primary neuronal cells.
Herpes simplex virus (HSV) causes many disease states including mucosal lesions, encephalitis or disseminated infection in the immunocompromised host. These diverse clinical manifestations reflect the capacity of the virus to infect both epithelial and neuronal cell types. Determining the requirements for virus entry into both cell types may provide insights into the pathogenesis of HSV. Previous studies have focused on identifying viral and cellular requirements for entry using epithelial cells. However, little is known about the requirements for binding and entry into neuronal cells. The purpose of the studies reported here was to identify viral and cellular components involved in entry of HSV-1 into primary neuronal cells. Heparan sulfate glycosaminoglycans were found to serve as a receptor for entry of HSV-1 into primary neuronal cells. Evidence to support this includes the findings that heparin (an analogue of heparan sulfate) competitively inhibited virus binding and expression of immediate early virus gene products. In addition, heparitinase removed viral receptors and inhibited virus entry. In epithelial cells, deletion of HSV-1 glycoprotein C (gC) results in virions that have reduced specific binding activity (virus particles bound per cell) and specific infectivity. However, in neuronal cells, it was found that deletion of gC resulted in no loss in specific binding activity, but did result in significant impairment of virus entry as measured by expression of immediate early viral gene product. Taken together, these findings suggest cell-type differences in virus binding and entry and a different role for gC in neuronal cell infection.
Immergluck
L C
LC
Department of Pediatrics, The University of Chicago, IL 60637, USA. limmergl@uic.edu
Domowicz
M S
MS
Schwartz
N B
NB
Herold
B C
BC
D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000821:virology; D002642:Chick Embryo; D002522:Chlorocebus aethiops; D019765:Chondroitin ABC Lyase / Q000494:pharmacology; D004848:Epithelium / Q000187:drug effects / Q000821:virology; D005347:Fibroblasts / Q000187:drug effects / Q000821:virology; D005697:Galactosides; D019812:Heparan Sulfate Proteoglycans / Q000502:physiology*; D006493:Heparin / Q000031:analogs & derivatives / Q000494:pharmacology; D018259:Herpesvirus 1, Human / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D007211:Indoles; D009474:Neurons / Q000187:drug effects / Q000821:virology*; D011133:Polysaccharide-Lyases / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000502:physiology
D005697:Galactosides; D019812:Heparan Sulfate Proteoglycans; D007211:Indoles; D014759:Viral Envelope Proteins; C038535:glycoprotein gC, herpes simplex virus type 1; D006493:Heparin; D011133:Polysaccharide-Lyases; D019765:Chondroitin ABC Lyase; C021349:heparitinsulfate lyase; C044888:5-bromo-4-chloro-3-indolyl beta-galactoside